Fungal Infection Clinical Trial
Official title:
Systemic Fungal Infections in Intensive Care Unit Patients
This study aims to :
1. Diagnosis of Systemic fungal infections in ICU patients.
2. Detection the most common fungal species in ICU.
3. Detection of in vitro antifungal sensitivity pattern
Status | Not yet recruiting |
Enrollment | 100 |
Est. completion date | October 15, 2019 |
Est. primary completion date | September 1, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - Suppressed immunity such as: (patients with malignancy under chemotherapy, prolonged use of corticosteroids.………etc) - Manifestations of chest infection e.g.cough, Haemoptysis, dyspnea and chest discomfort. - Persistent fever resistant to antibiotic therapy. - Urinary manifestations resistant to antibiotic therapy. Exclusion Criteria: - Patients who received antifungal therapy within 3 days prior to sample collection. - Patients refused to participate in the study. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Assiut University |
Jensen J, Guinea J, Torres-Narbona M, Muñoz P, Peláez T, Bouza E. Post-surgical invasive aspergillosis: an uncommon and under-appreciated entity. J Infect. 2010 Feb;60(2):162-7. doi: 10.1016/j.jinf.2009.11.005. Epub 2009 Nov 20. — View Citation
Leleu G, Aegerter P, Guidet B; Collège des Utilisateurs de Base de Données en Réanimation. Systemic candidiasis in intensive care units: a multicenter, matched-cohort study. J Crit Care. 2002 Sep;17(3):168-75. — View Citation
O'Keefe SJ, Sender PM, Clark CG, James WP. Proceedings: The dynamics of protein metabolism following operative trauma. Clin Sci Mol Med. 1974 Sep;47(3):15P. — View Citation
Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ, Zaoutis TE, Sobel JD. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016 Feb 15;62(4):e1-50. doi: 10.1093/cid/civ933. Epub 2015 Dec 16. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Positive cultures of collected specimens from patients in ICU with suspected SFI. | samples (blood ,urine and sputum) will be taken under complete aseptic precautions in sterile containers and carried immediately for culturing on sabouraud dextrose agar .Positive cultures help in early diagnosis of systemic fungal infections | 2weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03641131 -
Ampholipad Real-World Data in Taiwan
|
||
Completed |
NCT01371656 -
Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation
|
Phase 3 | |
Completed |
NCT00936117 -
Pharmacokinetics of Posaconazole Prophylaxis in Acute Leukemia
|
Phase 2 | |
Completed |
NCT00740389 -
TMC125-TiDP2-C187: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Interaction Between TMC125 and Two Antifungal Agents (Fluconazole and Voriconazole), All at Steady-state in Healthy Subjects.
|
Phase 1 | |
Completed |
NCT03857399 -
Empiric Therapy of Patients With Persistent Fever and Agranulocytosis Using Caspofungin
|
Phase 2 | |
Not yet recruiting |
NCT04215458 -
Microbiota in Skin and Mucosa of Patients With Inflammatory Skin Diseases
|
N/A | |
Completed |
NCT03667690 -
Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis
|
Phase 3 | |
Completed |
NCT02957929 -
Safety, Pharmacokinetics, Bioavailability, Food Effect, Drug-Drug Interaction Study of APX001 Administered Orally
|
Phase 1 | |
Completed |
NCT01419678 -
Pharmacokinetic Analysis of Posaconazole in Lung Transplant Recipients
|
N/A | |
Recruiting |
NCT00333645 -
Prophylaxis With Caspofungin in High-Risk Liver Transplantation
|
Phase 2 | |
Not yet recruiting |
NCT03650439 -
Fungal Infections in Patients With Hematological Malignancies
|
||
Completed |
NCT01303549 -
Anidulafungin vs Amphotericin B Safety in High Risk Hepatic Transplant Recipients
|
Phase 4 | |
Withdrawn |
NCT00430469 -
Safety of hLF1-11 for the Treatment of Infectious Complications Among HSCT Recipients
|
Phase 1/Phase 2 | |
Completed |
NCT00811642 -
Posaconazole Treatment of Invasive Fungal Infection (IFI) (P05551)
|
Phase 3 | |
Terminated |
NCT00386997 -
ProphyALL - Study on the Safety of Liposomal Amphotericin B to Prevent Antifungal Infections in Elderly Patients With Acute Lymphoblastic Leukemia
|
Phase 4 | |
Completed |
NCT00514358 -
Fluconazole Pharmacokinetics in Infants
|
Phase 1 | |
Completed |
NCT04166669 -
A Drug-Drug Interaction Study of CYP3A4 Inhibition and Pan-CYP Induction on APX001
|
Phase 1 | |
Recruiting |
NCT05150327 -
Multicenter Cohort Study of Invasive Fungal Filamentous Fungal Infections in Liver Transplant Patients
|
||
Completed |
NCT02387983 -
Pharmacokinetics and Safety of Oral Posaconazole (MK-5592)Tablets in Chinese Participants at High Risk for Invasive Fungal Infections (MK-5592-117)
|
Phase 1 | |
Not yet recruiting |
NCT06417983 -
Topical Application of Essential Oils to Treat Onchomycosis
|